Is CAR-T safe for early-stage patients?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: CAR-T
STAT+: New CAR-T company, Brainchild Bio, will focus first on brain tumors in children
About a decade ago, Mike Jensen, a pediatric oncologist at Seattle Children’s hospital, licensed to…
Now 18, the first child to ever receive CAR-T cancer therapy is ready for a new identity
The Food and Drug Administration approves dozens of cancer drugs every year, but the vast…
STAT+: Kite to buy Tmunity Therapeutics, Carl June’s troubled CAR-T startup
Kite Pharma, Gilead’s cell therapy subsidiary, said on Tuesday it would buy Tmunity, a biotech…
Virtual event: CAR-T comes of age?
Editor’s note: A livestream of this event will be embedded below at 1 p.m. ET. …
STAT+: New data on CRISPR Therapeutics’ off-the-shelf CAR-T cancer therapy shows more remissions, no major safety issues
More of the cancer patients who received CRISPR Therapeutics’ experimental, off-the-shelf CAR-T cell therapy showed…
STAT Plus: Additional blood cancer responses seen with Allogene’s off-the-shelf CAR-T cells, updated study shows
Allogene on Friday released updated results from the first study of its off-the-shelf CAR-T cell…
STAT Plus: Vindicated. New J&J CAR-T myeloma data confirm strong efficacy, ease doubts raised by Chinese version
ORLANDO, Fla. — One year ago, a Chinese scientist stepped up to a podium at…
STAT Plus: New data show Bluebird, Bristol CAR-T drug could be pioneering myeloma therapy. Competitors may be close behind
ORLANDO, Fla. — On the eve of a major blood disease research meeting here, Bluebird…